Business
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy human subjectsATLANTA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumati
About this update from Alzamend Neuro, Inc.
[{"type":"image","alt":"Alzamend Neuro, Inc.","displaySize":"","headline":null,"caption":"Alzamend Neuro, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":71,"url":"https://media.zenfs.com/en/globenewswire.com/beaa4f3451e46424f3f01617d10e3695"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_uEJOJXjxPyeOYcOwc1Xqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/beaa4f3451e46424f3f01617d10e3695","width":300,"height":71}},"lazy":false},{"type":"text","content":"Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy human subjects","length":193,"tagName":"p"},{"type":"text","content":"ATLANTA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced its plans to initiate the first of five highly anticipated phase II clinical studies of AL001, with the first study, in healthy human subjects, expected to commence in the second quarter of 2025. This study follows the successful development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial.","length":679,"tagName":"p"},{"type":"text","content":"In collaboration with Massachusetts General Hospital as its contract research organization, Alzamend aims to explore the unique properties of AL001 and its effects on lithium delivery in the brain compared to marketed lithium salts. The study in healthy human subjects will serve as a baseline and could illuminate the path forward in Alzheimer’s, BD, MDD, and PTSD patients by demonstrating AL001’s targeted effectiveness and reduced systemic side effects. Previous studies in mice have shown that AL001 ensures better brain absorption while maintaining lower levels of lithium in the blood, paving the way for safer and more efficient treatments.","length":648,"tagName":"p"},{"type":"text","content":"By offering a treatment that potentially eliminates the need for lithium therapeutic drug monitoring (“TDM”), AL001 could revolutionize care for vulnera...